HYDROXOCOBALAMIN

Post-LOE

hydroxocobalamin

Teva

ANDAINJECTIONINJECTABLE

Approved

Aug 1978

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

Drug Shortage Active

HYDROXOCOBALAMIN is currently in shortage. Reason: Limited Availability. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.

HYDROXOCOBALAMIN (hydroxocobalamin) by Teva is clinical pharmacology vitamin b 12 is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis. Approved for multiple sclerosis. First approved in 1978.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Vitamin B 12 is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis. Fifty percent of the administered dose of hydroxocobalamin disappears from the injection site in 2.5 hours. Hydroxocobalamin is bound to plasma proteins and stored in the…

Indications (1)

multiple sclerosis

Company

Worked on HYDROXOCOBALAMIN at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.